科研之友
微信
新浪微博
Facebook
分享链接
摘要
psoriasis affects 0.12% to 0.71% of all children. erythrodermic psoriasis is an uncommon but serious disorder, occurring in less than 1.5% of cases. tumor necrosis factor-alpha blockers (tnf-汐) are a new class of drugs used to treat moderate to severe psoriasis refractory to conventional therapies. etanercept is a tnf汐 receptor fusion protein, approved by the fda for treating juvenile rheumatoid arthritis. we present the case of a 7-year-old suffering from plaque psoriasis since 8 months old which evolved into erythroderma refractory to cyclosporine and methotrexate. patient responded excellently to etanercept, with no adverse side effects
